2011-08-01T09:06:07-04:00 2010-12-31 ARGY WILTSE & ROBINSON PC 8405 GREENSBORO DRIVE 7TH FLOOR MCLEAN VA 22102 990 2010-01-01 912059167 CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC CYST 3019514422 6931 ARLINGTON ROAD BETHESDA MD 20814 ROBERT J BEALL PHD 2011-07-23 7038930600 2010 2016-02-24 21:20:13Z ROBERT J BEALL PHD 6931 ARLINGTON ROAD STE 200 BETHESDA MD 20814 54161930 false X www.CFF.ORG/RESEARCH/CFFT/ X 2000 MD The mission is to assure the development of the means to cure and control cystic fibrosis (cf) and to improve the quality of life for those with the disease. 6 5 11 0 0 0 54285326 0 0 400446 0 369 35876 53761115 54321202 54161930 29566742 29412613 0 0 2624177 2842375 0 0 0 22130283 21906942 54321202 54161930 0 24668970 67639625 24668970 67639625 0 THE MISSION IS TO ASSURE THE DEVELOPMENT OF THE MEANS TO CURE AND CONTROL CYSTIC FIBROSIS (CF) AND TO IMPROVE THE QUALITY OF LIFE FOR THOSE WITH THE DISEASE. A LIFE SHORTENING GENETIC DISEASE, CF AFFECTS THE LUNGS AND DIGESTIVE SYSTEMS OF NEARLY 30,000 CHILDREN AND YOUNG ADULTS IN THE U.S. CURRENTLY, THERE IS NO CURE. false false 11625382 0 0 Investments by Cystic Fibrosis Foundation Therapeutics (CFFT) in state-of-the-art research have accelerated progress toward developing new CF treatments and finding a cure for the disease. By investing in CF drug discovery and development research conducted by biotechnology companies and providing matching awards to CF drug developers for CF research, and with a specialized CF clinical trials network, CFFT has attracted significant industry involvement in the fight against CF. Cayston, a new inhaled antibiotic developed by Gilead Sciences, Inc., was approved in 2010 by the FDA. This was the first drug to progress completely through CFFT's Therapeutics Development Program and it offers an antibiotic alternative for CF patients who battle recurrent lung infections and often develop resistance to existing antibiotics. At the end of 2010, CFFT supported nearly 30 potential CF drug therapies in various stages of development. 42239783 29412613 400446 Medical Programs in 2010 consisted of costs to support scientific study and investigations. 200 grants were awarded in 2010. 53865165 true false false false false false false false false true false false false true true false true false false true true false false false false false true false true false false false false false false false false false false false false false true false false false false true 47 0 true 11 true false false false false false false false false false false X 6 5 false false false false false true false true true false false true true true true true true true true false X X X ROBERT J BEALL PHD 3019514422 6931 ARLINGTON ROAD STE 200 BETHESDA MD 20814 X Catherine C McLoud 3.0 X 0 0 0 D PAUL FLESSNER 3.0 X 0 0 0 JONATHAN COHN MD 3.0 X 0 0 0 Steven Shak MD 3.0 X 0 0 0 Theodore J Torphy PhD 3.0 X 0 0 0 Robert J Beall PhD 18.0 X X 198548 403094 239406 C Richard Mattingly 5.0 X 0 427271 172432 Preston W Campbell MD 18.0 X 140934 278976 157898 Vera H Twigg 5.0 X 0 273807 82369 BRUCE MARSHALL MD 50.0 X 270515 0 25128 MARTIN MENSE 50.0 X 132787 0 28412 CYNTHIA GEORGE MSN FNP BC 50.0 X 107372 0 15442 850156 1383148 721087 5 false true false FOLDRX PHARMACEUTICALS INC 100 ACORN PARK DRIVE CAMBRIDGE MA 02140 THERAPEUTICS DISC 4003786 CHANTEST INC 14556 NEO PARKWAY CLEVELAND OH 44128 THERAPEUTICS DISC 2275000 ALBANY MEDICAL RESEARCH INC 26 RESEARCH CIRCLE ALBANY NY 12212 THERAPEUTICS DISC 1890694 NAT'L DISEASE RESEARCH INTERCHANGE 1628 JOHN F KENNEDY BLVD PHILADELPHIA PA 19103 CLINICAL MATERIAL 237000 PROMEDDX LLC 10 COMMERCE WAY NORTON MA 02766 TESTING SERVICES 197654 10 0 CLINICAL STUDY 541900 180000 180000 REFUNDED OR CANCELLED GRANTS 900099 220446 220446 400446 369 369 0 53761115 53761115 0 0 0 0 0 54161930 400446 53761484 26529182 26529182 0 2883431 2883431 0 733313 672948 60365 0 0 1804180 1655661 148519 0 66021 60586 5435 0 108038 99144 8894 0 130823 119689 11134 0 0 184806 184806 0 0 4790 0 4790 0 0 0 0 171036 167729 3307 0 0 83711 69445 14266 0 242641 232009 10632 0 0 200413 180608 19805 0 125194 121253 3941 0 0 54001 52899 1102 0 0 11352615 11352615 0 0 71899 69463 2436 0 150316 150316 0 0 CONTRACTED RESEARCH 9260950 9260950 0 0 TRAINING 4570 2431 2139 0 54161930 53865165 296765 0 821382 0 1171289 1068631 192 66488635 39442 32500 300684 250825 90491 49859 22546174 0 24668970 67639625 191156 16758245 24477814 22749014 0 28132366 24668970 67639625 X 0 0 24668970 67639625 0 0 X false true true X false X X X false false false CYSTIC FIBROSIS FOUNDATION 131930701 07 true true true 11352615 1 11352615 300684 250825 49859 49859 0 INTERCOMPANY PAYABLE 28132366 28132366 FIN 48 FOOTNOTE FORM 990 SCHEDULE D, PART X, LINE 2 IN 2009, THE FOUNDATION ADOPTED AUTHORITATIVE GUIDANCE SPECIFIC TO THE ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. THE ADOPTION DID NOT HAVE A MATERIAL EFFECT ON THE FINANCIAL STATEMENTS. true North America 0 0 Grantmaking none 789132 Europe (Including Iceland and Greenland) 0 0 Grantmaking none 1216962 East Asia and the Pacific 0 0 Grantmaking none 794339 Middle East and North Africa 0 0 Grantmaking none 82998 0 0 0 0 2883431 2883431 North America CLIN RESEAR 57049 CHECK North America CLIN RESEAR 100863 CHECK North America DRUG DISCOV 98560 CHECK North America DRUG DISCOV 216000 CHECK North America DRUG DISCOV 262660 CHECK North America DRUG DISCOV 54000 CHECK Europe/Iceland/Greenland CLIN RESEAR 232725 WIRE Europe/Iceland/Greenland CLIN RESEAR 93100 CHECK Europe/Iceland/Greenland CLIN RESEAR 305594 CHECK Europe/Iceland/Greenland Drug DISCOV 100000 CHECK Europe/Iceland/Greenland DRUG DISCOV 168927 CHECK Europe/Iceland/Greenland DRUG DISCOV 203303 WIRE Europe/Iceland/Greenland DRUG DISCOV 113313 WIRE East Asia/Pacific CLIN TRIAL 794339 CHECK Middle East/North Africa DRUG DISCOV 82998 CHECK 15 0 false false false false false false Procedures for monitoring grant funds outside of the U.S. Schedule F, Part I, Line 2 THE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANTS AWARDED TO ENTITIES OUTSIDE OF THE UNITED STATES. THE ORGANIZATION FOLLOWS THE U.S. DEPARTMENT OF TREASURY ANTI-TERRORIST FINANCING VOLUNTARY BEST PRACTICES GUIDELINES FOR CHARITIES. IN COMPLIANCE WITH THE BEST PRACTICES, THE ORGANIZATION COLLECTS AND REVIEWS INFORMATION ABOUT THE PROSPECTIVE GRANTEE INSTITUTIONS AND CONDUCTS A VETTING PROCESS TO ENSURE THEY ARE NOT SUSPECTED OF ACTIVITIES RELATED TO TERRORISM. ONCE A GRANT IS APPROVED, A WRITTEN AGREEMENT IS SIGNED BY BOTH THE ORGANIZATION AND THE GRANTEE. SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO DETERMINE PROGRESS. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE CF FOUNDATION'S INTERNAL AUDITORS CONDUCT AUDITS ON SAMPLES OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS. THE GRANT IN THE MIDDLE EAST/NORTH AFRICA REGION WAS MADE TO A UNIVERSITY IN ISRAEL. true Albany Medical College Albany NY 12208 Albany NY 12208 141338310 501c(3) 71820 CLINICAL RESEARCH Arizona Board of Regents University of Arizona Tucson AZ 85722 Tucson AZ 85722 742652689 501c(3) 187951 CLINICAL RESEARCH Atlantic Health System Morristown NJ 07962 Morristown NJ 07962 521958352 501c(3) 61560 CLINICAL RESEARCH Baylor College of Medicine Houston TX 77212 Houston TX 77212 741613878 501c(3) 78491 CLINICAL RESEARCH Case Western Reserve University Cleveland OH 44106-7015 Cleveland OH 441067015 341018992 501c(3) 458961 CLINICAL RESEARCH CFRx Lab LLC Charlestown MA 02129 Charlestown MA 02129 042763837 501c(3) 551264 DRUG DISCOVERY Children's & Women's Physicians of Westchester LL Valhalla NY 10595 Valhalla NY 10595 133940462 501c(3) 71820 CLINICAL RESEARCH Children's Health Care Minneapolis MN 55404-1844 Minneapolis MN 554041844 411754276 501c(3) 61560 CLINICAL RESEARCH Children's Hospital Corporation Boston MA 02115 Suite 208 Boston MA 02115 042774441 501c(3) 102600 CLINICAL RESEARCH Children's Hospital Medical Center of Akron Akron OH 44308 Munger Pavilion Room 123 Akron OH 44308 340714357 501c(3) 82080 CLINICAL RESEARCH Children's Hospital Medical Center Cincinnati Cincinnati OH 45229 Cincinnati OH 45229 310833936 501c(3) 423461 CLINICAL RESEARCH Children's Medical Center Dayton OH 45404 Dayton OH 45404 310672132 501c(3) 71820 CLINICAL RESEARCH Children's Memorial Hospital Chicago IL 60614 Chicago IL 60614 363357006 501c(3) 172800 CLINICAL RESEARCH Children's Mercy Hospital Kansas City MO 61408 Kansas City MO 61408 440605373 501c(3) 82080 CLINICAL RESEARCH Connecticut Children's Medical Center Hartford CT 06106 Hartford CT 06106 060646755 501c(3) 79454 CLINICAL RESEARCH Cook Children's Medical Center Ft Worth TX 76104 Ft Worth TX 76104 752051646 501c(3) 71820 CLINICAL RESEARCH Drexel University College of Medicine Philadelphia PA 19129-1191 Philadelphia PA 191291191 232979433 501c(3) 82080 CLINICAL RESEARCH Duke University Medical Center Durham NC 27710 Durham NC 27710 560532129 501c(3) 61560 CLINICAL RESEARCH Emory University Atlanta GA 30322 Atlanta GA 30322 580566256 501c(3) 102600 CLINICAL RESEARCH Indiana University Indianapolis IN 46266-6057 Indianapolis IN 462666057 356001673 501c(3) 102369 CLINICAL RESEARCH Kaiser Foundation Research Institute Oakland CA 94612 Oakland CA 94612 941105628 501c(3) 61560 CLINICAL RESEARCH LSUMC - Shreveport Shreveport LA 71130 Shreveport LA 71130 720702002 501c(3) 61560 CLINICAL RESEARCH Maine Medical Center Portland ME 04102-3175 Portland ME 041023175 010238552 501c(3) 236645 CLINICAL RESEARCH Maine Medical Center Portland ME 04102-3175 Portland ME 041023175 010238552 501c(3) 71820 CLINICAL RESEARCH Medical College of Georgia Atlanta GA 30394 Atlanta GA 30394 586002053 501c(3) 79209 CLINICAL RESEARCH Medical University of South Carolina Charleston SC 29402 Charleston SC 29402 576000722 501c(3) 149903 CLINICAL RESEARCH Medical University of South Carolina Charleston SC 29402 Charleston SC 29402 576000722 501c(3) 24754 ACADEMIC ADVISORY AWARDS Monmouth Medical Center Foundation Long Branch NJ 07740 Long Branch NJ 07740 222456079 501c(3) 71820 CLINICAL RESEARCH Nemours Children's Clinic Orlando Orlando FL 32801 Orlando FL 32801 590634433 501c(3) 232792 CLINICAL RESEARCH Oregon Health & Sciences University Portland OR 97201 Portland OR 97201 237083114 501c(3) 52920 CLINICAL RESEARCH Oregon Health & Sciences University Portland OR 97201 Portland OR 97201 237083114 501c(3) 270000 DRUG DISCOVERY Pennsylvania State University Hershey PA 17033 Hershey PA 17033 246000376 501c(3) 82080 CLINICAL RESEARCH Phoenix Children's Hospital Phoenix AZ 85006 Phoenix AZ 85006 860422559 501c(3) 71820 CLINICAL RESEARCH Providence Alaska Medical Center Anchorage AK 99508 L-106 Anchorage AK 99508 510216586 501c(3) 41599 CLINICAL RESEARCH Regents of the University of Colorado at Denver an Aurora CO 80045 Aurora CO 80045 846000555 501c(3) 226504 CLINICAL RESEARCH Rosalind Franklin University of Medicine and Scien North Chicago IL 60064 North Chicago IL 60064 362181973 501c(3) 398912 DRUG DISCOVERY Sanford Clinic Sioux Falls SD 57117 Sioux Falls SD 57117 460447693 501c(3) 61560 CLINICAL RESEARCH Seattle Children's Hospital Seattle WA 98105 13123 East 16th Avenue B395 Seattle WA 98105 910564748 501c(3) 3005545 CLINICAL TRIALS Seattle Children's Hospital Seattle WA 98105 Seattle WA 98105 910564748 501c(3) 5003553 CLINICAL RESEARCH Spectrum Health Grand Rapids MI 49503 Grand Rapids MI 49503 382752328 501c(3) 71820 CLINICAL RESEARCH St Luke's Regional Medical Center Boise ID 83712 Boise ID 83712 820161600 501c(3) 61560 CLINICAL RESEARCH Stanford University Stanford CA 94305-6215 Stanford CA 943056215 941156365 501c(3) 474140 CLINICAL RESEARCH Stanford University Stanford CA 94305-6215 Stanford CA 943056215 941156365 501c(3) 108000 DRUG DISCOVERY SUNY Upstate Medical University Syracuse NY 13210 Syracuse NY 13210 141368361 501c(3) 76361 CLINICAL RESEARCH Texas Tech University Health Sciences Center Lubbock TX 79430 Lubbock TX 79430 752668014 501c(3) 105594 DRUG DISCOVERY The Children's Hospital Association Aurora CO 80045 Aurora CO 80045 840166760 501c(3) 618907 CLINICAL RESEARCH The Children's Hospital of Philadelphia Philadelphia PA 19104 Philadelphia PA 19104 231352166 501c(3) 101261 CLINICAL RESEARCH The Cystic Fibrosis Center at St Vincent's Hospit New York NY 10011 New York NY 10011 135562343 501c(3) 35910 CLINICAL RESEARCH The General Hospital Corporation (aka Massachuse Boston MA 02114 Boston MA 02114 042697983 501c(3) 85271 DRUG DISCOVERY The General Hospital Corporation (aka Massachuse Boston MA 02114 Boston MA 02114 042697983 501c(3) 82080 CLINICAL RESEARCH The Hitchcock Foundation Lebanon NH 03756 Lebanon NH 03756 020222139 501c(3) 71820 CLINICAL RESEARCH The Johns Hopkins University Baltimore MD 21205 Baltimore MD 21205 520595110 501c(3) 791988 CLINICAL RESEARCH The Johns Hopkins University Baltimore MD 21205 Baltimore MD 21205 520595110 501c(3) 291600 DRUG DISCOVERY The Medical College of Wisconsin Milwaukee WI 53226 Milwaukee WI 53226 390806261 501c(3) 75872 CLINICAL RESEARCH The Rector and Visitors of the University of Virgi Charlottesville VA 22904-4195 MC0831 Charlottesville VA 229044195 546001796 501c(3) 82080 CLINICAL RESEARCH The Regents of the University of California San D La Jolla CA 92093-0984 MC0831 La Jolla CA 920930984 956006144 501c(3) 130557 CLINICAL RESEARCH The Regents of the University of California San D La Jolla CA 92093-0984 Room 1044 La Jolla CA 920930984 956006144 501c(3) 324000 DRUG DISCOVERY The Regents of The University of Michigan Ann Arbor MI 48109-1274 Room 1044 Ann Arbor MI 481091274 386006309 501c(3) 499126 CLINICAL RESEARCH The Regents of the University of Minnesota Minneapolis MN 55455-2070 200 Oak Street SE Suite 450 Minneapolis MN 554552070 416007513 501c(3) 172800 CLINICAL RESEARCH The Research Institute at Nationwide Children's Ho Columbus OH 43205 Columbus OH 43205 316056230 501c(3) 75188 DRUG DISCOVERY The Research Institute at Nationwide Children's Ho Columbus OH 43205 Columbus OH 43205 316056230 501c(3) 172800 CLINICAL RESEARCH The Scripps Research Institute La Jolla CA 92037 General Post Office La Jolla CA 92037 330435954 501c(3) 504000 DRUG DISCOVERY The Trustees of Columbia University in the City of New York NY 10087-9789 General Post Office New York NY 100879789 135598093 501c(3) 63240 DRUG DISCOVERY The Trustees of Columbia University in the City of New York NY 10087-9789 New York NY 100879789 135598093 501c(3) 82080 CLINICAL RESEARCH The Trustees of Columbia University in the City of New York NY 10087-9789 New York NY 100879789 135598093 501c(3) 44920 ACADEMIC ADVISORY AWARDS The University of Alabama at Birmingham Birmingham AL 35233 Suite 620 ACC Birmingham AL 35233 636005396 501c(3) 1014632 DRUG DISCOVERY The University of Alabama at Birmingham Birmingham AL 35233 Suite 620 ACC Birmingham AL 35233 636005396 501c(3) 347922 CLINICAL RESEARCH The University of Alabama at Birmingham Birmingham AL 35233 970 E 58th Street Birmingham AL 35233 636005396 501c(3) 56841 ACADEMIC ADVISORY AWARDS The University of Chicago Chicago IL 60637 Chicago IL 60637 362177139 501c(3) 61560 CLINICAL RESEARCH The University of Iowa Iowa City IA 52242 Division of Sponsored Programs Iowa City IA 52242 426004813 501c(3) 263207 DRUG DISCOVERY The University of Iowa Iowa City IA 52242 Iowa City IA 52242 426004813 501c(3) 172800 CLINICAL RESEARCH The University of North Carolina at Chapel Hill Chapel Hill NC 27599-4100 Chapel Hill NC 275994100 566001393 501c(3) 673368 CLINICAL RESEARCH The University of North Carolina at Chapel Hill Chapel Hill NC 27599-4100 Chapel Hill NC 275994100 566001393 501c(3) 789363 CLINICAL TRIALS The University of North Carolina at Chapel Hill Chapel Hill NC 27599-4100 Dept of Microbiology and Immunolog Chapel Hill NC 275994100 566001393 501c(3) 1071552 DRUG DISCOVERY The University of North Carolina at Chapel Hill Chapel Hill NC 27599-4100 Chapel Hill NC 275994100 566001393 501c(3) 25861 ACADEMIC ADVISORY AWARDS The University of Vermont and State Agricultural C Burlington VT 5405 2nd Floor Burlington VT 05405 030179440 501c(3) 82080 CLINICAL RESEARCH Toledo Children's Hospital Toledo OH 43606 438 Whitney Road Ext U-1133 Toledo OH 43606 344428256 501c(3) 82080 CLINICAL RESEARCH Trustees of Dartmouth College Hanover NH 03755-1404 Hanover NH 037551404 020222111 501c(3) 62429 ACADEMIC ADVISORY AWARDS University at Buffalo Pediatric Associates Buffalo NY 14222 Buffalo NY 14222 161238821 501c(3) 82080 CLINICAL RESEARCH University at Buffalo Pediatric Associates Buffalo NY 14222 Buffalo NY 14222 161238821 501c(3) 179896 ACADEMIC ADVISORY AWARDS University of Connecticut Storrs CT 06269-1133 Storrs CT 062691133 060772160 501c(3) 97134 DRUG DISCOVERY University of Kentucky Research Foundation Lexington KY 40506-0005 Lexington KY 405060005 616033693 501c(3) 81700 CLINICAL RESEARCH University of Massachusetts Medical School Worcester MA 01655 Worcester MA 01655 043167352 501c(3) 61560 CLINICAL RESEARCH University of Miami Miami FL 33102-5405 Miami FL 331025405 590624458 501c(3) 71474 CLINICAL RESEARCH University of Nebraska Medical Center Omaha NE 68198-5190 Omaha NE 681985190 470491233 501c(3) 82080 CLINICAL RESEARCH University of New Mexico Health Sciences Center Albuquerque NM 87131-0001 601 Elmwood Avenue Albuquerque NM 871310001 856000642 501c(3) 39708 CLINICAL RESEARCH University of Oklahoma Health Sciences Center Oklahoma City OK 73190 Oklahoma City OK 73190 736017987 501c(3) 71820 CLINICAL RESEARCH University of Pittsburgh Pittsburgh PA 15260 Pittsburgh PA 15260 250965591 501c(3) 476667 DRUG DISCOVERY University of Pittsburgh Pittsburgh PA 15260 Pittsburgh PA 15260 250965591 501c(3) 208758 CLINICAL RESEARCH University of Rochester Medical Center Rochester NY 14642 Rochester NY 14642 160743209 501c(3) 82080 CLINICAL RESEARCH University of South Alabama Mobile AL 36688 Mobile AL 36688 630477348 501c(3) 108000 DRUG DISCOVERY University of Southern California Los Angeles CA 90033 Los Angeles CA 90033 951642394 501c(3) 61560 CLINICAL RESEARCH University of Tennessee Memphis TN 38163 Memphis TN 38163 626001636 501c(3) 76930 CLINICAL RESEARCH University of Texas Health Science Center at San A San Antonio TX 78229 San Antonio TX 78229 741586031 501c(3) 71820 CLINICAL RESEARCH University of Utah Salt Lake City UT 84102 Salt Lake City UT 84102 876000525 501c(3) 102600 CLINICAL RESEARCH University of Washington Seattle WA 98105-6692 Seattle WA 981056692 916001537 501c(3) 313321 CLINICAL RESEARCH University of Wisconsin Board of Regents Madison WI 53706 Madison WI 53706 396006492 501c(3) 263134 CLINICAL RESEARCH UT Southwestern Medical Center at Dallas Dallas TX 75390-9040 Dallas TX 753909040 756002868 501c(3) 292964 DRUG DISCOVERY Vanderbilt University Medical Center Nashville TN 37241-0195 Nashville TN 372410195 620476822 501c(3) 82080 CLINICAL RESEARCH Via Christi Regional Medical Center Inc Wichita KS 67214 Research and Sponsored Programs Wichita KS 67214 481172106 501c(3) 61560 CLINICAL RESEARCH Virginia Commonwealth University Richmond VA 23284-2506 One Waterfront Place Richmond VA 232842506 546001758 501c(3) 81482 CLINICAL RESEARCH Washington University St Louis MO 63110 PO Box 208047 St Louis MO 63110 430653611 501c(3) 190080 CLINICAL RESEARCH Wayne State University Detroit MI 48201 Detroit MI 48201 383028425 501c(3) 82080 CLINICAL RESEARCH West Virginia University Research Corporation Morgantown WV 26506-6001 Morgantown WV 265066001 550665758 501c(3) 52686 CLINICAL RESEARCH Yale University New Haven CT 06520-8047 New Haven CT 065208047 060646973 501c(3) 60968 CLINICAL RESEARCH 87 0 PROCEDURES FOR MONITORING GRANT FUNDS INSIDE OF THE U.S. PART I, LINE 2 THE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANT FUNDS AWARDED TO ENTITIES INSIDE OF THE US. SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED AND APPROVED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO DETERMINE PROGRESS. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE CF FOUNDATION'S INTERNAL AUDITORS CONDUCT AUDITS ON A SAMPLE OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS. X X X X X X false true false false false false false false false Robert J Beall PhD 164014 323652 26599 54003 7935 25439 63690 154438 0 21275 262238 578807 26599 54003 C Richard Mattingly 0 345800 0 62006 0 19465 0 149016 0 23416 0 599703 0 62006 Preston W Campbell MD 115272 222712 20217 41046 5445 15218 34498 95170 0 28230 175432 402376 20217 41046 Vera H Twigg 0 237095 0 25969 0 10743 0 54772 0 27597 0 356176 0 25969 BRUCE MARSHALL MD 268193 0 0 0 2322 0 25128 0 0 0 295643 0 0 0 MARTIN MENSE 132511 0 276 0 0 0 3015 0 25397 0 161199 0 0 0 SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B Part I, Line 4b: Certain persons listed in Form 990, Part VII, Section A participate in a nonqualified deferred compensation plan, under which interests are forfeited by the participant if the participant voluntarily terminates employment prior to designated vesting date. Further information about the nonqualified deferred compensation plan in which those persons participate is provided in the additional information for Schedule J, Part II, below. COMPENSATION PART II Cystic Fibrosis Foundation Therapeutics, Inc. EIN 91-2059167. (A) Name: R. Beall, Ph.D.; (B)(i) Base Compensation: base salary - $156,754, 401(k) bonus - $7,260; (B)(ii) Bonus & Incentive Compensation : long-term incentive plan payment, which was previously reported (1) - $26,599; (B)(iii) Other Reportable Compensation: health insurance benefit - $1,434, automobile allowance - $2,376, other benefits including general organization group term life insurance premiums - $4,125; (C) Deferred Compensation: long-term incentive plan benefits (6) - $31,350, SERP (3) - $32,340; (D) Nontaxable Benefits: $0 Cystic Fibrosis Foundation - Headquarters. (A) Name: R. Beall, Ph.D.; (B)(i) Base Compensation: base salary - $308,912, 401(k) bonus - $14,740; (B)(ii) Bonus & Incentive Compensation: long-term incentive plan payment, which was previously reported (1) - $54,003; (B)(iii) Other Reportable Compensation: health insurance benefit - $2,912, automobile allowance - $4,824, other benefits including taxable general organization group term life insurance premiums - $17,703; (C) Deferred Compensation: retirement benefit (2) - $25,128, long-term incentive plan benefits (6) - $63,650, SERP (3) - $65,660; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $11,932, employee contribution to flexible spending account benefit - $5,000, employee contribution to general organization health plan benefit - $4,346 Cystic Fibrosis Foundation Therapeutics, Inc. EIN 91-2059167. (A) Name: P. Campbell, M.D.; (B)(i) Base Compensation: base salary - $115,272; (B)(ii) Bonus & Incentive Compensation: long-term incentive plan payment, which was previously reported (1) - $20,217; (B)(iii) Other Reportable Compensation: Section 457(b) Plan (5) - $5,445; (C) Deferred Compensation: long-term incentive plan benefit (6) - $23,077, SERP (4) - $11,421; (D) Nontaxable Benefits: $0 Cystic Fibrosis Foundation - Headquarters. (A) Name: P. Campbell, M.D.; (B)(i) Base Compensation: base salary - $222,712; (B)(ii) Bonus & Incentive Compensation: long-term incentive plan payment, which was previously reported (1) - $41,046; (B)(iii) Other Reportable Compensation: other benefits including taxable general organization group term life insurance premiums - $4,163, Section 457(b) Plan (5) - $11,055; (C) Deferred Compensation: retirement benefit (2) - $25,128, long-term incentive plan benefits (6) - $46,855, SERP (4) - $23,187; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $16,905, employee contribution to flexible spending account benefit - $5,000, employee contribution to general organization health plan benefit - $6,325 Cystic Fibrosis Foundation - Headquarters. Name: (A) R. Mattingly; (B)(i) Base Compensation: base salary - $345,800; (B)(ii) Bonus & Incentive Compensation: long-term incentive plan payment, which was previously reported (1) - $62,006; (B)(iii) Other Reportable Compensation: Section 457(b) Plan (5) - $16,500; other benefits including taxable general organization group term life insurance premiums - $2,965; (C) Deferred Compensation: retirement benefit (2) - $25,128, long-term incentive plan benefit (6) - $70,780, SERP (4) - $53,108; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $15,273, employee contribution to flexible spending account benefit - $2,500, employee contribution to general organization health plan benefit - $5,640 Cystic Fibrosis Foundation - Headquarters. (A) Name: V. Twigg; (B)(i) Base Compensation: base salary - $237,095; (B)(ii) Bonus & Incentive Compensation: long-term incentive plan payment, which was previously reported (1)- $25,969; (B)(iii) Other Reportable Compensation: taxable general organization group term life insurance premiums - $1,368, Section 457(b) Plan (5) - $9,375; (C) Deferred Compensation: retirement benefit (2) - $25,128, long-term incentive plan benefit (6) - $29,644; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $17,908, employee contribution to flexible spending account benefit - $5,000, employee contribution to general organization health plan benefit - $4,689 (1) This figure represents payment of an award that accrued over a three-year performance period (years 2007-2009), and which was based on achievement of long term performance standards established in advance by the Compensation Committee. As required, this award was reported as "Deferred Compensation" on prior years' Forms 990 in each year it accrued and therefore (as required by the instructions) is double-reported here. (2) This is the employer contribution made under the Cystic Fibrosis Foundation 401(k) Plan for the 2010 Plan Year. (3) The SERP is sponsored by CFF, a related organization. The executive participates by virtue of being an officer of CFF. CFFT makes contributions on the participant's behalf to the SERP. A. This is an unvested employer contribution to the SERP. B. SERP interests are forfeited by the participant if the participant voluntarily terminates employment prior to December 31, 2012. C. SERP interests are held in a trust subject to the claims of CFF's bankruptcy creditors. In the event of a CFF bankruptcy, participants would become general unsecured creditors of CFF. D. The SERP is a nonqualified deferred compensation plan. This means that participants do not receive the tax benefits available to participants in tax qualified retirement plans. E. The SERP's design was reviewed and opined upon as reasonable by an independent compensation consultant. SERP contribution amounts were determined by an independent actuary. For example, under current law, interests under those arrangements are reportable as taxable compensation when they become vested, even if those amounts are not yet payable to the participant (and even if those amounts are never paid to the participant). F. CFF retains the right to amend or terminate the SERP at any time. (4) The SERP is sponsored by CFF, a related organization. The executive participates by virtue of being an officer of CFF. CFFT makes contributions on the participant's behalf to the SERP. A. This is an unvested employer contribution to the SERP. B. SERP interests are forfeited by the participant if the participant voluntarily terminates employment prior to attaining age 60. C. In the event of a CFF bankruptcy, participants are general unsecured creditors of CFF. D. The SERP is a nonqualified deferred compensation plan. This means that participants do not receive the tax benefits available to participants in tax qualified retirement plans. E. The SERP's design was reviewed and opined upon as reasonable by an independent compensation consultant. An independent actuary developed the contribution formula pursuant to which SERP contribution amounts are determined. F. CFF retains the right to amend or terminate the SERP at any time. (5) The 457(b) Plan is sponsored by CFF, a related organization. The executive participates by virtue of being an officer of CFF. CFFT makes contributions on the participant's behalf to the Plan. A. This is a vested contribution to the 457(b) Plan for the reporting period. B. In the event of a CFF bankruptcy, participants are general unsecured creditors of CFF. C. Distributions from the 457(b) Plan may not be rolled-over to an IRA or qualified plan (but may only be rolled-over to another 457(b) plan). D. The 457(b) Plan's design was reviewed and opined upon as reasonable by an independent compensation consultant. An independent actuary developed the contribution formula pursuant to which 457(b) contribution amounts are determined. Contributions to the 457(b) Plan are subject to annual IRS limits (currently $16,500). E. CFF retains the right to amend or terminate the 457(b) Plan at any time. (6) This Plan provides for awards related to a 3-year performance period, which ends on 12/31/12, based on achievement of performance objectives established in advance by the Compensation Committee. The individual must be employed on 12/31/12 to be eligible to receive full payment of the award. As required by the Form 990 instructions, this reported amount is an estimate of the portion of the award that accrued under the Plan by the executive for performance in 2010 but it has not been earned, awarded or paid under the Plan. GOVERNING BODY APPOINTMENTS Part VI, Section A, Line 7a (Page 6 Core Form) Certain of the Organization's board members are designated by the Board of Trustees of the Cystic Fibrosis Foundation. REVIEW OF 990 BY GOVERNING BODY Part VI, Section B, Line 11b (Page 6 Core Form) The Organization's Board of Directors receives a draft of the Form 990 prior to its being filed, with sufficient time for review and comment allowed. The Compensation Committee AND the Organization's ERISA attorneys review the executive compensation sections of the Form 990 to ensure completeness and accuracy. The Audit Committee also reviews the Form 990 as part of its chartered responsibilities. CONFLICT OF INTEREST MONITORING Part VI, Section B, Line 12c (Page 6 Core Form) A conflict of interest disclosure statement is completed annually by each Board member and officer. Disclosures provided are reported to the Nominating and Governance Committee, the Audit Committee and the Board of Trustees. As required within the bylaws, any potential conflicts of interest must be reported to the Board as they arise. When any matter is deemed a potential conflict of interest and requires action by the Board of Trustees, the interested trustee or officer is required to retire from the room in which the Board or its committee is meeting, may not participate in the final deliberation of the matter, and may not vote on the matter. The Organization enforced the policy during 2010 and had no conflicts of interest as defined by the policy. DETERMINING COMPENSATION Part VI, Section B, Line 15a and 15b (Page 6 Core Form) The total compensation of executives at the Organization is specifically designed to attract and retain the highest qualified executive and medical talent to fulfill the critically important mission of assuring the development of the means to cure and control CF and improving the quality of life for those with the disease. Cystic Fibrosis Foundation Therapeutics, Inc. shares officers with Cystic Fibrosis Foundation, a related organization. The independent Compensation Committee of the CF Foundation's Board of Trustees (who also is independent with respect to CFFT and its officers) follows the process described in the IRS intermediate sanctions rules when determining compensation for the CFFT / CFF officers. Specifically, the Committee: (1) Is composed entirely of non-employee volunteer directors who have no familial, business or significant personal relationships with the Organization or its executives. (2) Assesses the short-term and long-term contribution and performance of each executive in meeting very definitive and quantifiable objectives focused on the CF Foundation's mission success. (3) Engages an independent compensation consulting firm to compile appropriate comparability data (including compensation market information for peers with whom the CF Foundation competes for executive talent) for committee reliance. The committee meets with representatives of the consulting firm to review this data in detail. (4) Reviews all elements of each executive's total compensation, including but not limited to base salary, bonuses, perquisites, fringe benefits, and incentive and deferred compensation arrangements. Upon the executive's hire, and at each point in time thereafter at which a new or revised compensation arrangement is under consideration with respect to the executive, the committee meets with its independent compensation consulting firm before the arrangement is implemented to evaluate the reasonableness of the arrangement by comparing both the arrangement itself and the executive's entire compensation package to compensation packages paid by similarly situated organizations for functionally comparable positions. (5) Documents, concurrently with its determination, the basis for its determination in the minutes of its meeting. These minutes are reviewed, revised if necessary and approved at the following meeting of the committee. (6) Obtains a written legal opinion concerning the committee's compliance with the IRS intermediate sanctions rules. The process described above was used to establish compensation for the cfft/cff officeRs or positions: President & CEO Executive Vice President & COO Executive Vice President for Medical Affairs Senior Vice President & CFO The process was last undertaken in 2009. PUBLIC INSPECTION Part VI, Section C, Line 19 (Page 6 Core Form) Forms 1023 and 990-T for the Organization are available on its website, CFF.org. The Organization's website provides a link to Guidestar.org for access to Form 990. The Foundation's governing documents (Bylaws and Articles of Incorporation) are available upon request by contacting the National Office of the Cystic Fibrosis Foundation in writing or by phone. Information on how to obtain the governing documents is also available on the Foundation's website, www.cff.org. The Board and Officer Conflict of Interest Policy and the audited financial statements are available on the Foundation's website, www.cff.org. HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:Robert J. Beall, Ph.D. TITLE:President & CEO HOURS:39 HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:C. Richard Mattingly TITLE:Exec VP and COO HOURS:55 HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:Preston W. Campbell, MD TITLE:Exec VP of Medical Affairs HOURS:39 HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:Vera H. Twigg TITLE:Sr. VP and CFO HOURS:55 CYSTIC FIBROSIS FOUNDATION-HEADQUARTERS 6931 ARLINGTON RD bethesda MD 20814 131930701 research DE 501(C)(3) 7 na CYSTIC FIBROSIS FOUNDATION - GROUP 6931 ARLINGTON RD BETHESDA MD 20814 136161105 EDUCATION DE 501(C)(3) 7 CFF-HQ CYSTIC FIBROSIS SERVICES INC 6931 ARLINGTON RD BETHESDA MD 20814 521850490 pharmacy MD CFF PHARMACY c 0 0 0.00000 false true false false false false false false false false false false true true false false false false Cystic fibrosis foundation - headquarters 1B 11352615 Cystic fibrosis foundation - headquarters 1M 242527 Cystic fibrosis foundation - headquarters 1N 1684292